Neuronostatin-13 trifluoroacetate salt
|
|
|
- CAS号:
- 1096485-24-3
- 英文名:
- Neuronostatin-13 trifluoroacetate salt
- 英文别名:
- Neuronostatin-13 human;Neuronostatin trifluoroacetate salt;Neuronostatin-13 trifluoroacetate salt;Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2 trifluoroacetate salt;L-Alaninamide, L-leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-;L-Leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-L-alaninamide trifluoroacetate salt
- 中文名:
- Neuronostatin-13 trifluoroacetate salt
- 中文别名:
- 生长抑素基因编码多肽;生长抑素基因编码多肽NEURONOSTATIN-13 HUMAN
- CBNumber:
- CB02750578
- 分子式:
- C64H110N20O16
- 分子量:
- 1415.68
- MOL File:
- 1096485-24-3.mol
|
|
|
Neuronostatin-13 trifluoroacetate salt化学性质
-
密度:
-
1.39±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
-20°C
-
|
-
酸度系数(pKa):
-
12.90±0.46(Predicted)
-
|
-
形态:
-
lyophilized solid
-
|
-
颜色:
-
white
-
|
Neuronostatin-13 trifluoroacetate salt性质、用途与生产工艺
Neuronostatin-13 human 是一种由生长抑素基因编码的由 13 个氨基酸组成的肽激素，在调节激素和心脏功能中起着重要作用。
Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function. Treatment with Neuronostatin-13 human (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human leads to an increase in phosphorylated PKA at 30 and 40 min.
Infusion with Neuronostatin-13 human delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human challenge. In addition, Neuronostatin-13 human treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human treatment.
Neuronostatin-13 trifluoroacetate salt
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-P1373 | Neuronostatin-13 trifluoroacetate salt
Neuronostatin-13 (human) | 1096485-24-3 | 1mg | 2200元 |
| 2024/04/30 | HY-P1373 | Neuronostatin-13 trifluoroacetate salt
Neuronostatin-13 (human) | 1096485-24-3 | 5mg | 6600元 |
Neuronostatin-13 trifluoroacetate salt
生产厂家
1096485-24-3, Neuronostatin-13 trifluoroacetate salt 相关搜索:
- 目录多肽
- 目录肽
- 标准品
- C64H110N20O16
- 生长抑素基因编码多肽
- 生长抑素基因编码多肽NEURONOSTATIN-13 HUMAN
- 1096485-24-3
- L-Alaninamide, L-leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-
- Neuronostatin-13 human
- Neuronostatin-13 trifluoroacetate salt
- Neuronostatin trifluoroacetate salt
- L-Leucyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-lysyl-L-seryl-L-leucyl-L-alanyl-L-alanyl-L-alanyl-L-alaninamide trifluoroacetate salt
- Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2 trifluoroacetate salt